Home
About Us
Membership
Member Biography

Member Biography

Mateusz Opyrchal, MD, PhD

Mateusz Opyrchal, M.D., Ph.D.

Phone: (317) 944-0920, Patient issues/appointments

545 Barnhill Drive
EH 305
Indianapolis, IN 46202

Faculty appointments

Associate Professor of Medicine, Department of Medicine, Division of Hematology/Oncology, IU School of Medicine
Vera Bradley Foundation Scholar in Breast Cancer Discovery
Director, Early Phase Clinical Trial Program, IU Simon Comprehensive Cancer Center
Full member, Experimental and Developmental Therapeutics (Leader)

A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY OF ORAL MRT-2359 IN PATIENTS WITH MYC-DRIVEN AND OTHER SELECTED SOLID TUMORS INCLUDING LUNG CANCER AND DIFFUSE LARGE B-CELL LYMPHOMACTO-MRT-2359-001

A Phase I/II, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108(an Anti-CCR8 mAb) as a Single Agent or in Combination with Pembrolizumab in Advanced Solid TumorsCTO-LM108-01-102

A Multicenter Phase I/Ib Dose Escalation Study of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Patients with Selected Advanced or Metastatic Solid TumorsCTO-WTX-124X2101

A Phase 1, Open-Label, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of IMM2902 in Patients with HER2-Expressing Advanced Solid TumorsCTO-IMM2902-101

A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY159 as a Single Agent and In Combination with Pembrolizumab in Subjects with Advanced Solid TumorsCTO-PY159-2-01

A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study of IO-202 in Combination with Pembrolizumab in Subjects with Advanced, Relapsed, or Refractory Solid TumorsCTO-IO-202-CL-002

A Phase I, First-In-Human, Multicenter, Open Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety and Efficacy of ABM-168 Administered Orally in Adult Patients with Advanced Solid TumorsCTO-ABM168X1101

A Phase 1 (First-In-Human [FIH]), Multi-Site, Dose Escalation and Expansion Study of WTX-330 in Adult Patients with Advanced or Metastatic Solid Tumors or LymphomaCTO-WTX-330X2101

Organoid model predictive of response to immunotherapiesCTO-IUSCCC-0804

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE)CTO-PMV-586-101

Headlines & highlights

#ResearchCuresCancer

Support Our Research